IRIS
MINOTTI, GIORGIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 661
EU - Europa 355
AS - Asia 116
OC - Oceania 33
SA - Sud America 13
AF - Africa 3
Totale 1.181
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 632
GB - Regno Unito 207
IN - India 43
IT - Italia 37
DE - Germania 33
AU - Australia 32
CA - Canada 28
BE - Belgio 20
CN - Cina 16
JP - Giappone 11
TR - Turchia 11
NL - Olanda 8
HK - Hong Kong 7
RU - Federazione Russa 7
FR - Francia 5
AR - Argentina 4
CL - Cile 4
ES - Italia 4
FI - Finlandia 4
HU - Ungheria 4
ID - Indonesia 4
BR - Brasile 3
EE - Estonia 3
MY - Malesia 3
RO - Romania 3
SE - Svezia 3
SG - Singapore 3
TW - Taiwan 3
AL - Albania 2
BA - Bosnia-Erzegovina 2
BY - Bielorussia 2
IE - Irlanda 2
IR - Iran 2
PL - Polonia 2
SI - Slovenia 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AZ - Azerbaigian 1
BD - Bangladesh 1
CH - Svizzera 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
EC - Ecuador 1
EG - Egitto 1
HR - Croazia 1
IL - Israele 1
IQ - Iraq 1
JO - Giordania 1
KW - Kuwait 1
KZ - Kazakistan 1
LK - Sri Lanka 1
MA - Marocco 1
NZ - Nuova Zelanda 1
PE - Perù 1
PH - Filippine 1
PT - Portogallo 1
RS - Serbia 1
SA - Arabia Saudita 1
TH - Thailandia 1
ZA - Sudafrica 1
Totale 1.181
Salva come PNG Salva come JPEG
Città #
Ashburn 282
London 196
Redmond 56
San Francisco 48
Council Bluffs 42
Boardman 34
Pune 34
Toronto 25
Rome 23
Washington 21
Melbourne 17
Hasselt 16
West Jordan 16
Seattle 14
Los Angeles 13
Canberra 10
Santa Clara 7
Haikou 6
Hanover 5
Sydney 5
Tokyo 5
Amsterdam 4
Bengaluru 4
Helsinki 4
Oklahoma City 4
Tenri 4
Almere Stad 3
Beijing 3
Budapest 3
Central 3
Chicago 3
Mol 3
New York 3
North Liberty 3
Paris 3
Petaling Jaya 3
Singapore 3
Taipei 3
Tallinn 3
Alba 2
Berlin 2
Buenos Aires 2
Charlotte 2
Dublin 2
Fremont 2
Hoellviken 2
Ljubljana 2
Lodz 2
Minsk 2
New Delhi 2
Penicuik 2
Reston 2
San Mateo 2
Sarajevo 2
Shenzhen 2
Tirana 2
A Coruña 1
Almaty 1
Amman 1
Asyut 1
Bandung 1
Bangkok 1
Belgrade 1
Bucharest 1
Central District 1
Centurion 1
Chiyoda-ku 1
Cleveland 1
Colombo 1
Columbia 1
Delhi 1
Dhaka 1
Frankfurt am Main 1
Garin 1
Giarre 1
Haifa 1
Hicksville 1
Huntington 1
Hyderabad 1
Jarrow 1
Krasnoyarsk 1
Kuwait City 1
La Poueze 1
Lima 1
Lincoln 1
Lisbon 1
Maasmechelen 1
Madrid 1
Manila 1
Markham 1
Milan 1
Mountain View 1
Naples 1
Padova 1
Quilpué 1
Quito 1
Rabat 1
Riyadh 1
Rockville 1
Spresiano 1
Totale 1.012
Salva come PNG Salva come JPEG
Nome #
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines 36
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement 22
Proceedings of an International Workshop on Anthracycline Cardiotoxicity 19
Early Diastolic Dysfunction after Cancer Chemotherapy: Primary Endpoint Results of a Multicenter Cardio-Oncology Study 18
Cancer incidence and mortality in patients diagnosed with heart failure: results from an updated systematic review and meta-analysis 14
Anthracycline Cardiotoxicity 14
Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium 13
Pixantrone: novel mode of action and clinical readouts. 13
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). 13
Pharmacology of Cardio-Oncology 13
Doxorubicin-Dependent Reduction of Ferrylmyoglobin and Inhibition of Lipid Peroxidation: Implications for Cardiotoxicity of Anticancer Anthracyclines 12
Factors influencing superoxide and t-BuOOH dependent lipid peroxidation of tumor microsomes 12
Anthracyclines: molecular advances and pharmacological developments in antitumor activity and cardiotoxicity 12
From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction: A Translational Approach 11
Doxorubicin irreversibly inactivates iron regulatory protein-1 and –2 in cardiomyocytes: evidence for distinct metabolic pathways and implication for iron-mediated cardiotoxicity of antitumor therapy 11
Matters of the heart: The case of TNF-alpha targeting drugs. 11
Low level tumor necrosis factor-alpha protects cardiomyocytes against high level tumor necrosis factor-alpha: brief insight into a beneficial paradox 11
Anthracyclines 11
CARDIAC ANTHRACYCLINE ACCUMULATION AND B-TYPE NATRIURETIC PEPTIDE TO DEFINE RISK AND PREDICTORS OF CANCER TREATMENT RELATED EARLY DIASTOLIC DYSFUNCTION 10
Sodium-Glucose Cotransporter Inhibitors Reduce Mortality and Morbidity in Patients With Heart Failure: Evidence From a Meta-Analysis of Randomized Trials 10
Doxorubicin metabolism and toxicity in human myocardium : Role of cytoplasmic deglycosidation and carbonyl reduction 10
The role of iron in the initiation of lipid peroxidation. 10
An Invitation from the Editors of Cardio-Oncology 10
Further analytical, pharmacokinetic, and clinical observations on low-dose ponatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia 10
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis 10
Modeling human myocardium exposure to doxorubicin defines the risk of heart failure from low-dose doxorubicin 10
Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review. 10
The concomitant management of cancer therapy and cardiac therapy 10
Cardiotoxicity of antitumor drugs 10
NEW TARGETED DRUGS FOR ACUTE MYELOID LEUKEMIA AND ANTIFUNGALS: PHARMACOKINETIC CHALLENGES AND OPPORTUNITIES 9
Mechanisms and clinical course of cardiovascular toxicity of cancer treatment II. Hematology 9
Quantitative evaluation of the activity of the malate-aspartate shuttle in Ehrlich ascites tumor cells. 9
Cardiovascular safety of anti-TNF-alpha therapies: Facts and unsettled issues. 9
Gamma-glutamyl transpeptidase-dependent iron reduction and LDL oxidation : a potential mechanism in atherosclerosis. 9
Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue 9
Cardiovascular events in cancer survivors 9
Oxidative degradation of cardiotoxic anticancer anthracyclines to phthalic acids. Novel function or ferrylmyoglobin 9
gamma-Glutamyl transpeptidase dependent iron reduction and LDL oxidation : characterization of a novel mechanism of atherogenesis 9
Cell Biology and Toxicology: Special Issue on Cardiovascular Liability of Drugs 9
Pharmacology of cardio-oncology: chronotropic and lusitropic effects of B-type natriuretic peptide in cancer patients with early diastolic dysfunction induced by anthracycline or nonanthracycline chemotherapy 8
Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology 8
Doxorubicin degradation in cardiomyocytes 8
Cancer drugs and QT prolongation: weighing risk against benefit 8
Pharmacology at work for cardio-oncology: ranolazine to treat early cardiotoxicity induced by antitumor drugs. 8
The endogenous lusitropic and chronotropic agent, B-type natriuretic peptide, limits cardiac troponin release in cancer patients with an early impairment of myocardial relaxation induced by anthracyclines 8
Iron regulatory proteins: from molecular mechanisms to drug development 8
Human heart cytosolic reductases and anthracycline cardiotoxicity. 8
Managing anthracycline-induced cardiotoxicity: beginning with the end in mind 8
Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding. 8
Helping the cardio-oncologist: from real life to guidelines. 8
Heart Rate reduction by IVabradine for improvement of ENDothELial function in patients with coronary artery disease: the RIVENDEL study. 8
The iron regulatory proteins: targets and modulators of free radical reactions and oxidative damage 8
Acute Heart Failure 29 Years After Treatment for Childhood Cancer 8
NADPH and adriamycin dependent microsomal release of iron and lipid peroxidation 8
Adriamycin alcohol dependent iron mobilization : A novel mechanism of adriamycin cardiotoxicity? 8
Taxanes stimolate Doxorubicin conversion to its cardiotoxic secondary alcohol metabolite doxorubicinol: studies in human myocardium 8
Anthracycline Cardiotoxicity 8
Drug-induced hepatotoxicity in cancer patients - implication for treatment 8
Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma 8
Doxorubicin paradoxically protects cardiomyocytes against iron-mediated toxicity: Role of reactive oxygen species and ferritin 7
Adriamycin dependent release of iron from microsomal membranes 7
Superoxide and hydrogen peroxide-dependent inhibition of iron regulatory protein activity: a protective stratagem against oxidative injury 7
The role of an endogenous nonheme iron in microsomal redox reactions. 7
Redox cycling of iron and lipid peroxidation 7
Cytochrome P-450 deficiency and resistance to tert-butyl hydroperoxide of hepatoma microsomal lipid peroxidation. 7
O2.--dependent lipid peroxidation does not affect the molecular order in hepatoma microsomes. 7
Anthracycline degradation in cardiomyocytes: a journey to oxidative survival 7
4’- Epidoxorubicin to reexplore anthracycline degradation in cardiomyocytes 7
The anthracyclines: When good things go bad. 7
What is cardiotoxicity? 7
Treatment specific toxicities: Hormones, antihormones, radiation therapy. 7
Role of secondary alcohol metabolites in anthracycline cardiotoxicity: from hypotheses to new drugs 7
Anthracycline metabolism and toxicity in human myocardyum: Comparisons between doxorubicin, epirubicin, and a novel disaccaride analogue with redeced formation and [4Fe-4S]-reactivity of its secondary alchol metabolite 7
Antioxidant effect of Coenzyme Q analogs on hemoprotein-mediated oxidative stress. 7
Anthracycline secondary alcohol metabolite formation in human or rabbit heart ; Biochemical aspects and pharmacological implications 7
Development of a tumor-specific photoactivatable doxorubicin prodrug. 7
Altered iron regulatory protein activities in doxorubicin-treated cardiomyocytes : Distinct roles of reactive oxygen species and of the secondary alcohol metabolite doxorubicinol 7
Silent myocardial ischaemia on cardiac SPECT with MIBI implies endotelian toxicity in cancer patients on multiagent chemotherapy 7
Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion. 7
Cardiovascular toxicity of antitumor drugs :Translating molecular mechanisms into clinical facts 7
Role of iron in anthracycline cardiotoxicity : New tunes for an old song ? 7
Cardio-oncological management of patients. 7
Doxorubicin irreversibly inactivates Iron Regulatory Proteins 1 and 2 in cardiomyocytes : Evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy 7
Anthracycline metabolism and toxicity in human myocardium : Comparisons between doxorubicin, epirubicin, and a novel disaccharide analogue with reduced formation and [4Fe-4S]-reactivity of its secondary alcohol metabolite 7
Ibrutinib and Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia: focus on atrial fibrillation and ventricular tachyarrhythmias/sudden cardiac death 7
Cardiac imaging in childhood cancer survivors: a state-of-the-art review 6
Fe(II) oxidation and Fe(III) incorporation by the M(r) 66,000 microsomal iron protein that stimulates NADPH oxidation 6
null 6
Antioxidant properties of 2,3-dimethoxy-5-methyl-6-(10-hydroxy)-decyl-1,4-benzoquinone. 6
Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: Implications for cardiotoxicity of doxorubicin-taxane chemotherapies 6
Effect of reactive oxygen species on Iron Regulatory Protein activity. 6
Editorial 6
Anthracyclines 6
Dexrazoxane for reducing anthracycline-related cardiotoxicity in children with cancer: An update of the evidence 6
Editorial: The Journal Chemotherapy Is for Cardio-Oncologists Too 6
Do you know pixantrone? 6
Efficacy and safety of novel oral anticoagulants versus low molecular weight heparin in cancer patients with venous thromboembolism: A systematic review and meta-analysis. 6
The Second Special Cardio-Oncology Issue of Progress in Pediatric Cardiology: Closing remarks and hopes for the future 6
Anthracycline cardiotoxicity in breast cancer patients: Synergism with trastuzumab and taxanes 6
New frontiers in Cardio-Oncology 6
Totale 898
Salva come PNG Salva come JPEG
Categoria #
all - tutte 42.114
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.114
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022538 0 5 0 1 0 1 2 221 7 7 7 287
2022/2023108 2 4 5 8 7 5 13 0 2 7 51 4
2023/2024689 22 88 29 55 99 330 9 29 6 22 0 0
Totale 1.335